

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort NeuroTech Limited

微創腦科學有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2172)

**PROPOSED CHANGE OF ENGLISH NAME OF THE COMPANY
AND
PROPOSED ADOPTION OF THE THIRD AMENDED AND RESTATED
MEMORANDUM AND ARTICLES OF ASSOCIATION**

PROPOSED CHANGE OF COMPANY ENGLISH NAME

The board (the “**Board**”) of directors (the “**Directors**”) of MicroPort NeuroTech Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) proposes to change the English name of the Company from “MicroPort NeuroTech Limited” to “MicroPort NeuroScientific Corporation” (the “**Proposed Change of English Name**”). The Chinese name of the Company will remain unchanged.

Conditions for the Proposed Change of English Name

The Proposed Change of English Name is subject to the following conditions:

- (a) the passing of a special resolution by the shareholders of the Company (the “**Shareholders**”) at the annual general meeting (the “**AGM**”) to be convened to approve the Proposed Change of English Name; and
- (b) the Registrar of Companies in the Cayman Islands approving the Proposed Change of English Name by issuing a certificate of incorporation on change of name.

The relevant filing with the Registrar of Companies in the Cayman Islands will be made after the passing of the special resolution at the AGM. Subject to the satisfaction of the conditions set out above, the Proposed Change of English Name will take effect from the date of issue of the certificate of incorporation on change of name by the Registrar of Companies in the Cayman Islands. The Company will then carry out all necessary filing procedures with the Companies Registry in Hong Kong.

Reasons for the Proposed Change of Company Name

The Company has established itself as one of the leading companies in the neuro-interventional therapeutic area, and has been looking into opportunities to expand its business to brain science and other related sectors.

The Board considers that the Proposed Change of Company Name will better align with the current Chinese name of the Company and reflect the Company's diversified strategic business plan and its future development direction.

In addition, the Board believes that the new English name of the Company will provide the Company with a new corporate image, which will benefit the Company's future business development. Therefore, the Board considers that the Proposed Change of Company Name is in the best interests of the Company and the Shareholders as a whole.

Effects of the Proposed Change of Company Name

The Proposed Change of Company Name will not affect the rights of the Shareholders or the daily operations and financial position of the Group.

All existing share certificates of the Company bearing the existing name of the Company will, after the Proposed Change of English Name becomes effective, continue to be evidence of legal title to the shares of the Company (the "**Shares**") and be valid for trading, settlement, registration and delivery purposes. There will not be any arrangement for free exchange of existing share certificates of the Company for new share certificates bearing the new English name of the Company (the "**New English Name**").

Any new share certificates of the Company bearing the New English Name will only be issued in subsequent issue of new Shares after the Proposed Change of English Name becomes effective. The English short name and Chinese short name of the Company remain unchanged.

PROPOSED ADOPTION OF THE THIRD AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION

The Board also proposes to amend and restate the existing Second Memorandum and Articles of Association (the "**Existing Memorandum and Articles of Association**") to reflect the Proposed Change of English Name with effect from the same time the Proposed Change of English Name takes effect.

The Board proposes to put forward to the Shareholders for approval at the AGM a special resolution to adopt the third amended and restated memorandum and articles of association of the Company (the “**Third Amended and Restated Memorandum and Articles of Association**”) in substitute for and to the exclusion of the Existing Memorandum and Articles of Association. The proposed adoption of the Third Amended and Restated Memorandum and Articles of Association is subject to the passing of the special resolution.

GENERAL

The AGM will be convened and held for the Shareholders to consider and, if thought fit, approve resolutions in relation to, among others, the Proposed Change of English Name and the proposed adoption of the Third Amended and Restated Memorandum and Articles of Association.

A circular containing details in relation to, among others, the Proposed Change of English Name and the proposed adoption of the Third Amended and Restated Memorandum and Articles of Association and a notice convening the AGM will be despatched to the Shareholders in due course. Further announcement(s) will be made by the Company to inform the Shareholders of, among other things, the effective date of the Proposed Change of English Name, adoption of the Third Amended and Restated Memorandum and Articles of Association as and when appropriate.

By Order of the Board
MicroPort NeuroTech Limited
Dr. Chang Zhaohua
Chairman and Non-executive Director

Hong Kong, 27 March 2024

As at the date of this announcement, the Board comprises Mr. Xie Zhiyong and Mr. Wang Yiqun Bruce as the executive directors; Dr. Chang Zhaohua, Mr. Wang Lin, Ms. Wu Xia and Mr. Sun Qingwei as the nonexecutive directors; and Dr. Xu Yi, Dr. Zhang Haixiao and Mr. Siu Chi Hung as the independent non-executive directors.